{
  "doc_id": "20d0f18bf40fcbab8fa46c0fa1b40211049e179a3fc1bfb18602ce8015ec2e5f",
  "chunk_entities": [
    {
      "chunk_id": "650fdb5edb2a7690c0a70a1a99269a53",
      "entities": [
        {
          "entity_type": "Effect",
          "entity_name": "psychoactive",
          "context": "Novel psychoactive substances of interest for psychiatry"
        }
      ]
    },
    {
      "chunk_id": "dbbdd543d6321faea5397ea9d8184ab7",
      "entities": [
        {
          "entity_type": "Disease",
          "entity_name": "acute/chronic psychopathological manifestations",
          "context": "onset of acute/chronic psychopathological manifestations"
        },
        {
          "entity_type": "Compound",
          "entity_name": "novel psychoactive substances",
          "context": "intake of a range of novel psychoactive substances"
        },
        {
          "entity_type": "Compound",
          "entity_name": "substances",
          "context": "few hundred substances available"
        },
        {
          "entity_type": "Disease",
          "entity_name": "psychopathological disturbances",
          "context": "the psychopathological disturbances they can produce"
        }
      ]
    },
    {
      "chunk_id": "ecd45f1fd1ee6b04225e229dffaf25ad",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "SC molecules",
          "context": "a few hundreds of SC molecules are currently available"
        },
        {
          "entity_type": "Compound",
          "entity_name": "SCs",
          "context": "SCs possess high/very high cannabinoid receptor binding affinity levels"
        },
        {
          "entity_type": "Effect",
          "entity_name": "cannabinoid receptor binding affinity",
          "context": "SCs possess high/very high cannabinoid receptor binding affinity levels"
        },
        {
          "entity_type": "Compound",
          "entity_name": "tetrahydrocannabinol",
          "context": "efficacy than tetrahydrocannabinol itself"
        },
        {
          "entity_type": "Compound",
          "entity_name": "SCs",
          "context": "some SCs show further pharmacodynamic actions"
        },
        {
          "entity_type": "Compound",
          "entity_name": "N-methyl-D-aspartate",
          "context": "N-methyl-D-aspartate (NMDA) receptor antagonism"
        },
        {
          "entity_type": "Effect",
          "entity_name": "NMDA receptor antagonism",
          "context": "N-methyl-D-aspartate (NMDA) receptor antagonism"
        },
        {
          "entity_type": "Compound",
          "entity_name": "monoamine oxidase",
          "context": "monoamine oxidase (MAO) inhibitory properties"
        },
        {
          "entity_type": "Effect",
          "entity_name": "MAO inhibitory properties",
          "context": "monoamine oxidase (MAO) inhibitory properties"
        },
        {
          "entity_type": "Compound",
          "entity_name": "SCs",
          "context": "almost all SCs possess indole-derived structures"
        },
        {
          "entity_type": "Compound",
          "entity_name": "indole",
          "context": "almost all SCs possess indole-derived structures"
        },
        {
          "entity_type": "Effect",
          "entity_name": "5-HT2A receptor dysfunction",
          "context": "facilitate 5-HT2A receptor dysfunction"
        },
        {
          "entity_type": "Disease",
          "entity_name": "hallucinations",
          "context": "associated with both hallucinations/psychosis"
        },
        {
          "entity_type": "Disease",
          "entity_name": "psychosis",
          "context": "associated with both hallucinations/psychosis"
        },
        {
          "entity_type": "Disease",
          "entity_name": "serotonin syndrome",
          "context": "and the serotonin syndrome"
        },
        {
          "entity_type": "Compound",
          "entity_name": "SC",
          "context": "the recent trend of SC fluorination"
        },
        {
          "entity_type": "Effect",
          "entity_name": "lipophilicity",
          "context": "increase the compounds' lipophilicity"
        },
        {
          "entity_type": "Effect",
          "entity_name": "enhancing the absorption through biological membranes",
          "context": "hence enhancing the absorption through biological membranes/blood brain barrier"
        }
      ]
    },
    {
      "chunk_id": "582900b8e7de4b285553204140171b95",
      "entities": [
        {
          "entity_type": "Effect",
          "entity_name": "agitation",
          "context": "characterized by agitation/anxiety"
        },
        {
          "entity_type": "Effect",
          "entity_name": "anxiety",
          "context": "characterized by agitation/anxiety"
        },
        {
          "entity_type": "Effect",
          "entity_name": "visual/auditory hallucinations",
          "context": "visual/auditory hallucinations"
        },
        {
          "entity_type": "Effect",
          "entity_name": "tachycardia",
          "context": "together with tachycardia"
        },
        {
          "entity_type": "Effect",
          "entity_name": "hypertension",
          "context": "tachycardia, hypertension"
        },
        {
          "entity_type": "Effect",
          "entity_name": "mydriasis",
          "context": "hypertension, mydriasis"
        },
        {
          "entity_type": "Effect",
          "entity_name": "hyperglycaemia",
          "context": "mydriasis, hyperglycaemia"
        },
        {
          "entity_type": "Effect",
          "entity_name": "dyspnoea",
          "context": "hyperglycaemia, dyspnoea"
        },
        {
          "entity_type": "Effect",
          "entity_name": "vomiting",
          "context": "dyspnoea, vomiting"
        },
        {
          "entity_type": "Effect",
          "entity_name": "seizures",
          "context": "vomiting and seizures"
        },
        {
          "entity_type": "Disease",
          "entity_name": "stroke",
          "context": "may include stroke"
        },
        {
          "entity_type": "Disease",
          "entity_name": "encephalopathy",
          "context": "stroke, encephalopathy"
        },
        {
          "entity_type": "Disease",
          "entity_name": "myocardial infarction",
          "context": "encephalopathy, myocardial infarction"
        },
        {
          "entity_type": "Disease",
          "entity_name": "acute kidney injuries",
          "context": "myocardial infarction and acute kidney injuries"
        }
      ]
    },
    {
      "chunk_id": "51e54cce87b985218219863a72208bd1",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "synthetic cathinones",
          "context": "synthetic cathinones are snorted"
        },
        {
          "entity_type": "Compound",
          "entity_name": "mephedrone",
          "context": "For mephedrone, the half-life"
        },
        {
          "entity_type": "Compound",
          "entity_name": "serotonin",
          "context": "potency levels on serotonin"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopamine",
          "context": "dopamine and noradrenaline pathways"
        },
        {
          "entity_type": "Compound",
          "entity_name": "noradrenaline",
          "context": "dopamine and noradrenaline pathways"
        },
        {
          "entity_type": "Effect",
          "entity_name": "sympathomimetic/amphetamine-like effects",
          "context": "possess sympathomimetic/amphetamine-like effects"
        }
      ]
    },
    {
      "chunk_id": "c25d4e5c6d42a1c92d4459fd177616c3",
      "entities": [
        {
          "entity_type": "Disease",
          "entity_name": "Fatalities",
          "context": "Fatalities have been associated with"
        },
        {
          "entity_type": "Compound",
          "entity_name": "mephedrone",
          "context": "associated with mephedrone"
        },
        {
          "entity_type": "Compound",
          "entity_name": "methylone",
          "context": "methylone and butylone"
        },
        {
          "entity_type": "Compound",
          "entity_name": "butylone",
          "context": "methylone and butylone"
        },
        {
          "entity_type": "Compound",
          "entity_name": "synthetic cathinones",
          "context": "proportion of synthetic cathinones\u2019 users"
        },
        {
          "entity_type": "Effect",
          "entity_name": "tolerance",
          "context": "users report tolerance"
        },
        {
          "entity_type": "Effect",
          "entity_name": "dependence",
          "context": "dependence or withdrawal symptoms"
        },
        {
          "entity_type": "Effect",
          "entity_name": "withdrawal symptoms",
          "context": "dependence or withdrawal symptoms"
        },
        {
          "entity_type": "Compound",
          "entity_name": "methcathinone",
          "context": "Abstinent methcathinone users"
        },
        {
          "entity_type": "Effect",
          "entity_name": "decreased striatal dopamine transporter density",
          "context": "present with decreased striatal dopamine transporter density"
        },
        {
          "entity_type": "Disease",
          "entity_name": "psychiatric problems",
          "context": "long-term psychiatric problems"
        }
      ]
    },
    {
      "chunk_id": "8d0d8f50a5f8482677cf6d183a0b1e86",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "MDMA",
          "context": "MDMA (\u201cEcstasy\u201d)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Ecstasy",
          "context": "MDMA (\u201cEcstasy\u201d)"
        },
        {
          "entity_type": "Effect",
          "entity_name": "psychedelic",
          "context": "psychedelic phenethylamine products"
        },
        {
          "entity_type": "Compound",
          "entity_name": "phenethylamine",
          "context": "psychedelic phenethylamine products"
        },
        {
          "entity_type": "Compound",
          "entity_name": "2C molecules",
          "context": "a few 2C molecules"
        }
      ]
    },
    {
      "chunk_id": "0213c9f2a9b5f38e5173e29d3442b0e9",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "2,5-dimethoxy-4-bromophenethylamine",
          "context": "2,5-dimethoxy-4-bromophenethylamine (2-CB, \u201cNexus\u201d)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "2-CB",
          "context": "2,5-dimethoxy-4-bromophenethylamine (2-CB, \u201cNexus\u201d)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Nexus",
          "context": "2,5-dimethoxy-4-bromophenethylamine (2-CB, \u201cNexus\u201d)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "2,5-dimethoxy-4-iodophenethylamine",
          "context": "2,5-dimethoxy-4-iodophenethylamine (2C-I)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "2C-I",
          "context": "2,5-dimethoxy-4-iodophenethylamine (2C-I)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "2,5-dimethoxy-4-ethylphenethylamine",
          "context": "2,5-dimethoxy-4-ethylphenethylamine (2C-E)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "2C-E",
          "context": "2,5-dimethoxy-4-ethylphenethylamine (2C-E)"
        },
        {
          "entity_type": "Effect",
          "entity_name": "affinity for 5-HT2A receptors",
          "context": "show affinity for 5-HT2A receptors"
        },
        {
          "entity_type": "Effect",
          "entity_name": "inhibit the dopamine/noradrenaline/serotonin reuptake",
          "context": "inhibit the dopamine/noradrenaline/serotonin reuptake"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopamine",
          "context": "inhibit the dopamine/noradrenaline/serotonin reuptake"
        },
        {
          "entity_type": "Compound",
          "entity_name": "noradrenaline",
          "context": "inhibit the dopamine/noradrenaline/serotonin reuptake"
        },
        {
          "entity_type": "Compound",
          "entity_name": "serotonin",
          "context": "inhibit the dopamine/noradrenaline/serotonin reuptake"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MDMA",
          "context": "ingested as MDMA substitutes"
        }
      ]
    },
    {
      "chunk_id": "40a583d5c32893201798760ee7880893",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "MDMA",
          "context": "MDMA-like drugs"
        },
        {
          "entity_type": "Effect",
          "entity_name": "enhanced mood",
          "context": "enhanced mood"
        },
        {
          "entity_type": "Effect",
          "entity_name": "increased energy",
          "context": "increased energy"
        },
        {
          "entity_type": "Effect",
          "entity_name": "openness",
          "context": "openness"
        },
        {
          "entity_type": "Effect",
          "entity_name": "perceptual alterations",
          "context": "perceptual alterations"
        },
        {
          "entity_type": "Effect",
          "entity_name": "serotonergic toxicity",
          "context": "serotonergic ... toxicity effects"
        },
        {
          "entity_type": "Effect",
          "entity_name": "sympathomimetic toxicity",
          "context": "sympathomimetic toxicity effects"
        },
        {
          "entity_type": "Disease",
          "entity_name": "tachycardia",
          "context": "including tachycardia"
        },
        {
          "entity_type": "Disease",
          "entity_name": "hypertension",
          "context": "hypertension"
        },
        {
          "entity_type": "Disease",
          "entity_name": "metabolic acidosis",
          "context": "metabolic acidosis"
        },
        {
          "entity_type": "Disease",
          "entity_name": "convulsions",
          "context": "convulsions"
        },
        {
          "entity_type": "Disease",
          "entity_name": "rhabdomyolysis",
          "context": "rhabdomyolysis"
        },
        {
          "entity_type": "Disease",
          "entity_name": "mydriasis",
          "context": "mydriasis"
        },
        {
          "entity_type": "Disease",
          "entity_name": "vomiting",
          "context": "vomiting"
        },
        {
          "entity_type": "Disease",
          "entity_name": "diarrhoea",
          "context": "diarrhoea"
        },
        {
          "entity_type": "Disease",
          "entity_name": "thrombocytopenia",
          "context": "thrombocytopenia"
        },
        {
          "entity_type": "Disease",
          "entity_name": "Acute renal failure",
          "context": "Acute renal failure"
        },
        {
          "entity_type": "Disease",
          "entity_name": "hyperthermia",
          "context": "hyperthermia"
        }
      ]
    },
    {
      "chunk_id": "9d29478aee1d8cb43d3a1dcc90d2ee94",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "3C-bromo-Dragonfly",
          "context": "3C-bromo-Dragonfly (\u201cB-Fly\u201d) has been described as a powerful/long lasting drug"
        },
        {
          "entity_type": "Compound",
          "entity_name": "B-Fly",
          "context": "3C-bromo-Dragonfly (\u201cB-Fly\u201d) has been described as a powerful/long lasting drug"
        },
        {
          "entity_type": "Effect",
          "entity_name": "powerful/long lasting",
          "context": "described as a powerful/long lasting drug"
        },
        {
          "entity_type": "Effect",
          "entity_name": "psychoactive effects",
          "context": "up to 3 days of psychoactive effects"
        },
        {
          "entity_type": "Effect",
          "entity_name": "hallucinations",
          "context": "associated with long-standing hallucinations"
        },
        {
          "entity_type": "Effect",
          "entity_name": "mood elevation",
          "context": "mood elevation"
        },
        {
          "entity_type": "Effect",
          "entity_name": "paranoid ideation",
          "context": "paranoid ideation"
        },
        {
          "entity_type": "Effect",
          "entity_name": "confusion",
          "context": "confusion"
        },
        {
          "entity_type": "Effect",
          "entity_name": "anxiety",
          "context": "anxiety"
        },
        {
          "entity_type": "Effect",
          "entity_name": "flashbacks",
          "context": "flashbacks"
        }
      ]
    },
    {
      "chunk_id": "b53563496e8702e30751254f5305b476",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "4,4\u2019-dimethylaminorex",
          "context": "4,4\u2019-dimethylaminorex (4,4\u2019-DMAR, \u201cSerotoni\u201d)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "4,4\u2019-DMAR",
          "context": "4,4\u2019-dimethylaminorex (4,4\u2019-DMAR, \u201cSerotoni\u201d)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Serotoni",
          "context": "4,4\u2019-dimethylaminorex (4,4\u2019-DMAR, \u201cSerotoni\u201d)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "aminorex",
          "context": "derivative of aminorex"
        },
        {
          "entity_type": "Effect",
          "entity_name": "deaths",
          "context": "associated in 2013/2014 with some 30 deaths"
        },
        {
          "entity_type": "Compound",
          "entity_name": "amphetamine-type stimulants",
          "context": "Similar to amphetamine-type stimulants"
        },
        {
          "entity_type": "Effect",
          "entity_name": "dopamine/noradrenaline releaser",
          "context": "is a potent dopamine/noradrenaline releaser"
        },
        {
          "entity_type": "Effect",
          "entity_name": "inhibiting the serotonin transporter",
          "context": "whilst inhibiting the serotonin transporter"
        },
        {
          "entity_type": "Effect",
          "entity_name": "euphoria",
          "context": "It produces euphoria"
        },
        {
          "entity_type": "Effect",
          "entity_name": "alertness",
          "context": "euphoria, alertness and agitation"
        },
        {
          "entity_type": "Effect",
          "entity_name": "agitation",
          "context": "alertness and agitation"
        },
        {
          "entity_type": "Disease",
          "entity_name": "Hyperthermia",
          "context": "Hyperthermia and cardiorespiratory problems"
        },
        {
          "entity_type": "Disease",
          "entity_name": "cardiorespiratory problems",
          "context": "and cardiorespiratory problems have also been described"
        }
      ]
    },
    {
      "chunk_id": "06504efb745ca802fd00787d74bd8892",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "methiopropamine",
          "context": "methiopropamine (MPA, \u201cBlow\u201d), a methamphetamine analogue"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MPA",
          "context": "methiopropamine (MPA, \u201cBlow\u201d)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Blow",
          "context": "methiopropamine (MPA, \u201cBlow\u201d)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "methamphetamine",
          "context": "a methamphetamine analogue"
        },
        {
          "entity_type": "Compound",
          "entity_name": "research chemical",
          "context": "advertised online as a \u201cresearch chemical\u201d"
        },
        {
          "entity_type": "Compound",
          "entity_name": "noradrenaline",
          "context": "selective noradrenaline/dopamine reuptake inhibitor"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopamine",
          "context": "selective noradrenaline/dopamine reuptake inhibitor"
        },
        {
          "entity_type": "Effect",
          "entity_name": "noradrenaline/dopamine reuptake inhibitor",
          "context": "Being a selective noradrenaline/dopamine reuptake inhibitor"
        },
        {
          "entity_type": "Effect",
          "entity_name": "euphoria",
          "context": "it produces euphoria"
        },
        {
          "entity_type": "Effect",
          "entity_name": "hallucinations",
          "context": "produces euphoria, hallucinations"
        },
        {
          "entity_type": "Effect",
          "entity_name": "alertness",
          "context": "hallucinations, alertness"
        },
        {
          "entity_type": "Effect",
          "entity_name": "sexual arousal",
          "context": "alertness and sexual arousal"
        },
        {
          "entity_type": "Effect",
          "entity_name": "loss of appetite",
          "context": "associated with loss of appetite"
        },
        {
          "entity_type": "Effect",
          "entity_name": "tachycardia",
          "context": "loss of appetite, tachycardia"
        },
        {
          "entity_type": "Effect",
          "entity_name": "anxiety",
          "context": "tachycardia, anxiety"
        },
        {
          "entity_type": "Effect",
          "entity_name": "nausea",
          "context": "anxiety, nausea"
        },
        {
          "entity_type": "Effect",
          "entity_name": "headache",
          "context": "nausea, headache"
        },
        {
          "entity_type": "Effect",
          "entity_name": "dizziness",
          "context": "headache, dizziness"
        },
        {
          "entity_type": "Effect",
          "entity_name": "skin irritation",
          "context": "dizziness, skin irritation"
        },
        {
          "entity_type": "Effect",
          "entity_name": "difficulty urinating",
          "context": "skin irritation, difficulty urinating"
        },
        {
          "entity_type": "Effect",
          "entity_name": "hangover effects",
          "context": "difficulty urinating and hangover effects"
        }
      ]
    },
    {
      "chunk_id": "0aa330a4173fc46e9a8d40d78f27e388",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "tryptamines",
          "context": "Most exogenous tryptamines"
        },
        {
          "entity_type": "Effect",
          "entity_name": "psychoactive",
          "context": "are psychoactive hallucinogens"
        },
        {
          "entity_type": "Effect",
          "entity_name": "hallucinogens",
          "context": "psychoactive hallucinogens found naturally"
        },
        {
          "entity_type": "Plant",
          "entity_name": "Delosperma species",
          "context": "in Delosperma species plants"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dimethyltryptamine",
          "context": "plants (dimethyltryptamine, DMT;"
        },
        {
          "entity_type": "Compound",
          "entity_name": "DMT",
          "context": "dimethyltryptamine, DMT;"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-MeO-DMT",
          "context": "DMT; 5-MeO-DMT)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "psilocin",
          "context": "fungi (psilocin; 4-OH-DMT)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "4-OH-DMT",
          "context": "psilocin; 4-OH-DMT)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "bufotenin",
          "context": "amphibians (bufotenin)."
        },
        {
          "entity_type": "Compound",
          "entity_name": "bufotenin",
          "context": "Endogenous bufotenin and DMT"
        },
        {
          "entity_type": "Compound",
          "entity_name": "DMT",
          "context": "bufotenin and DMT have been"
        }
      ]
    },
    {
      "chunk_id": "0d98c060ca8f28a83e574a7055c296c7",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "ketamine",
          "context": "When misused, ketamine can be injected"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "25-300 mg",
          "context": "in a dosage range of 25-300 mg"
        },
        {
          "entity_type": "Effect",
          "entity_name": "psychotropic effects",
          "context": "Its psychotropic effects include referential thinking"
        },
        {
          "entity_type": "Effect",
          "entity_name": "referential thinking",
          "context": "psychotropic effects include referential thinking"
        }
      ]
    },
    {
      "chunk_id": "00b408fcdd197f60616256ee463ab308",
      "entities": [
        {
          "entity_type": "Effect",
          "entity_name": "dissociation",
          "context": "dissociation, depersonalization, psychotic experiences"
        },
        {
          "entity_type": "Effect",
          "entity_name": "depersonalization",
          "context": "depersonalization, psychotic experiences and out-of-body/near death experiences"
        },
        {
          "entity_type": "Effect",
          "entity_name": "psychotic experiences",
          "context": "psychotic experiences and out-of-body/near death experiences"
        },
        {
          "entity_type": "Effect",
          "entity_name": "out-of-body/near death experiences",
          "context": "out-of-body/near death experiences (e.g., the \"K-hole\""
        },
        {
          "entity_type": "Effect",
          "entity_name": "K-hole",
          "context": "e.g., the \"K-hole\""
        },
        {
          "entity_type": "Effect",
          "entity_name": "tolerance",
          "context": "tolerance, dependence, withdrawal signs and flashbacks"
        },
        {
          "entity_type": "Effect",
          "entity_name": "dependence",
          "context": "dependence, withdrawal signs and flashbacks are described"
        },
        {
          "entity_type": "Effect",
          "entity_name": "withdrawal signs",
          "context": "withdrawal signs and flashbacks are described"
        },
        {
          "entity_type": "Effect",
          "entity_name": "flashbacks",
          "context": "flashbacks are described, with schizotypal symptoms"
        },
        {
          "entity_type": "Effect",
          "entity_name": "schizotypal symptoms",
          "context": "schizotypal symptoms and perceptual distortions possibly persisting"
        },
        {
          "entity_type": "Effect",
          "entity_name": "perceptual distortions",
          "context": "perceptual distortions possibly persisting after cessation"
        }
      ]
    },
    {
      "chunk_id": "196fa564ac05ba494d2ffddf9e9403b6",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "ketamine",
          "context": "recreational ketamine use"
        },
        {
          "entity_type": "Disease",
          "entity_name": "urological problems",
          "context": "both urological (\"k bladder\", e.g., dysuria, suprapubic pain, haematuria, decreased bladder capacitance, abnormal bladder histology, hydronephrosis)"
        },
        {
          "entity_type": "Disease",
          "entity_name": "k bladder",
          "context": "urological (\"k bladder\", e.g., dysuria"
        },
        {
          "entity_type": "Disease",
          "entity_name": "dysuria",
          "context": "e.g., dysuria, suprapubic pain"
        },
        {
          "entity_type": "Disease",
          "entity_name": "suprapubic pain",
          "context": "suprapubic pain, haematuria"
        },
        {
          "entity_type": "Disease",
          "entity_name": "haematuria",
          "context": "haematuria, decreased bladder capacitance"
        },
        {
          "entity_type": "Disease",
          "entity_name": "decreased bladder capacitance",
          "context": "decreased bladder capacitance, abnormal bladder histology"
        },
        {
          "entity_type": "Disease",
          "entity_name": "abnormal bladder histology",
          "context": "abnormal bladder histology, hydronephrosis"
        },
        {
          "entity_type": "Disease",
          "entity_name": "hydronephrosis",
          "context": "hydronephrosis)"
        },
        {
          "entity_type": "Disease",
          "entity_name": "intestinal problems",
          "context": "and intestinal (\"k cramps\") (153) problems."
        },
        {
          "entity_type": "Disease",
          "entity_name": "k cramps",
          "context": "intestinal (\"k cramps\")"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "High dosage",
          "context": "High dosage self-administration"
        },
        {
          "entity_type": "Effect",
          "entity_name": "toxicity",
          "context": "cardiovascular and respiratory toxicity."
        },
        {
          "entity_type": "Disease",
          "entity_name": "cardiovascular toxicity",
          "context": "both cardiovascular and respiratory toxicity."
        },
        {
          "entity_type": "Disease",
          "entity_name": "respiratory toxicity",
          "context": "cardiovascular and respiratory toxicity."
        },
        {
          "entity_type": "Disease",
          "entity_name": "Numbness",
          "context": "Numbness, muscle weakness and impaired perception"
        },
        {
          "entity_type": "Disease",
          "entity_name": "muscle weakness",
          "context": "muscle weakness and impaired perception"
        },
        {
          "entity_type": "Disease",
          "entity_name": "impaired perception",
          "context": "impaired perception can result in falls"
        },
        {
          "entity_type": "Disease",
          "entity_name": "falls",
          "context": "result in falls, trauma or burns."
        },
        {
          "entity_type": "Disease",
          "entity_name": "trauma",
          "context": "falls, trauma or burns."
        },
        {
          "entity_type": "Disease",
          "entity_name": "burns",
          "context": "trauma or burns."
        },
        {
          "entity_type": "Disease",
          "entity_name": "drowning",
          "context": "included drowning, death from hypothermia"
        },
        {
          "entity_type": "Disease",
          "entity_name": "hypothermia",
          "context": "death from hypothermia due to lying outside"
        },
        {
          "entity_type": "Disease",
          "entity_name": "traffic accidents",
          "context": "winter, traffic accidents and becoming a crime victim"
        }
      ]
    },
    {
      "chunk_id": "ce2cac45c02fe1c73706164ce3b4653c",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "Methoxetamine",
          "context": "Methoxetamine (MXE, \"Special M\") has recently entered the market"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MXE",
          "context": "Methoxetamine (MXE, \"Special M\") has recently entered the market"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Special M",
          "context": "Methoxetamine (MXE, \"Special M\") has recently entered the market"
        },
        {
          "entity_type": "Compound",
          "entity_name": "ketamine",
          "context": "structural analogue of ketamine"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "5-100 mg",
          "context": "at a dosage range of 5-100 mg"
        }
      ]
    },
    {
      "chunk_id": "ddd520cf6336950e9eadaa101558b971",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "Ecstasy",
          "context": "included in \u201cfake\u201d Ecstasy tablets"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-HT2A receptor agonist",
          "context": "It is an 5-HT2A receptor agonist"
        },
        {
          "entity_type": "Effect",
          "entity_name": "hallucinogenic effects",
          "context": "explains its hallucinogenic effects"
        }
      ]
    },
    {
      "chunk_id": "097fbc9709b30167f853e8c35519f7f0",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "Piperazines",
          "context": "Piperazines have become popular"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Ecstasy effects",
          "context": "mimic Ecstasy effects"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Molly",
          "context": "introduced \u201cMolly\u201d being typically an MDMA/piperazine combination"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MDMA",
          "context": "an MDMA/piperazine combination"
        },
        {
          "entity_type": "Compound",
          "entity_name": "piperazine",
          "context": "an MDMA/piperazine combination"
        },
        {
          "entity_type": "Compound",
          "entity_name": "amphetamine",
          "context": "similar to those of amphetamine"
        },
        {
          "entity_type": "Effect",
          "entity_name": "amphetamine-like effects",
          "context": "effects are similar to those of amphetamine"
        },
        {
          "entity_type": "Effect",
          "entity_name": "less intense effects",
          "context": "but less intense"
        },
        {
          "entity_type": "Effect",
          "entity_name": "stimulant effects",
          "context": "associated with stimulant effects"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "higher dosages",
          "context": "at higher dosages hallucinations can be reported"
        },
        {
          "entity_type": "Effect",
          "entity_name": "hallucinations",
          "context": "hallucinations can be reported"
        },
        {
          "entity_type": "Disease",
          "entity_name": "Seizures",
          "context": "Seizures can occur"
        },
        {
          "entity_type": "Compound",
          "entity_name": "piperazine",
          "context": "presenting with piperazine toxicity"
        },
        {
          "entity_type": "Disease",
          "entity_name": "hyponatremia",
          "context": "with hyponatremia"
        },
        {
          "entity_type": "Disease",
          "entity_name": "serotonin syndrome",
          "context": "serotonin syndrome and renal failure"
        },
        {
          "entity_type": "Disease",
          "entity_name": "renal failure",
          "context": "and renal failure having been described"
        }
      ]
    },
    {
      "chunk_id": "015d4506d84d67ee76e60382a79c2bfc",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "gabapentin",
          "context": "gabapentin abuse"
        },
        {
          "entity_type": "Effect",
          "entity_name": "euphoria",
          "context": "including euphoria"
        },
        {
          "entity_type": "Effect",
          "entity_name": "improved sociability",
          "context": "improved sociability"
        },
        {
          "entity_type": "Effect",
          "entity_name": "sedation",
          "context": "opiate-like sedation"
        },
        {
          "entity_type": "Effect",
          "entity_name": "psychedelic effects",
          "context": "psychedelic effects"
        },
        {
          "entity_type": "Compound",
          "entity_name": "pregabalin",
          "context": "pregabalin is considered"
        },
        {
          "entity_type": "Effect",
          "entity_name": "sedative effects",
          "context": "including sedative effects"
        },
        {
          "entity_type": "Effect",
          "entity_name": "euphoria",
          "context": "mixed with euphoria"
        },
        {
          "entity_type": "Effect",
          "entity_name": "dissociation",
          "context": "and dissociation"
        }
      ]
    },
    {
      "chunk_id": "4c07de809bc031bddbb51f578c8e3bd2",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "pregabalin",
          "context": "Misuse of pregabalin"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "3-20 times higher than the maximal dosage indicated",
          "context": "dosages up to 3-20 times higher than the maximal dosage indicated"
        },
        {
          "entity_type": "Compound",
          "entity_name": "pregabalin",
          "context": "in combination with pregabalin"
        },
        {
          "entity_type": "Compound",
          "entity_name": "gabapentin",
          "context": "or gabapentin"
        },
        {
          "entity_type": "Plant",
          "entity_name": "Cannabis sativa",
          "context": "including cannabis"
        },
        {
          "entity_type": "Compound",
          "entity_name": "ethanol",
          "context": "alcohol"
        },
        {
          "entity_type": "Compound",
          "entity_name": "lysergic acid",
          "context": "lysergic acid"
        },
        {
          "entity_type": "Compound",
          "entity_name": "amphetamine",
          "context": "amphetamine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "GHB",
          "context": "and GHB"
        }
      ]
    },
    {
      "chunk_id": "2a9bc9a90552ad521bf64eb416a2e20d",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "Phenazepam",
          "context": "Phenazepam (\u201cZinnie\u201d) is an old benzodiazepine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "benzodiazepine",
          "context": "Phenazepam (\u201cZinnie\u201d) is an old benzodiazepine"
        },
        {
          "entity_type": "Disease",
          "entity_name": "neurological disorders",
          "context": "treatment of a range of neurological disorders"
        },
        {
          "entity_type": "Disease",
          "entity_name": "alcohol withdrawal",
          "context": "alcohol withdrawal/anxiety"
        },
        {
          "entity_type": "Disease",
          "entity_name": "anxiety",
          "context": "alcohol withdrawal/anxiety"
        },
        {
          "entity_type": "Effect",
          "entity_name": "premedication",
          "context": "as a surgery premedication"
        },
        {
          "entity_type": "Compound",
          "entity_name": "diazepam",
          "context": "more powerful than diazepam"
        },
        {
          "entity_type": "Dosage",
          "entity_name": "five times",
          "context": "considered five times more powerful than diazepam"
        },
        {
          "entity_type": "Effect",
          "entity_name": "euphoric effects",
          "context": "with euphoric effects having been described"
        },
        {
          "entity_type": "Effect",
          "entity_name": "amnesia",
          "context": "side effects include amnesia"
        },
        {
          "entity_type": "Effect",
          "entity_name": "dizziness",
          "context": "amnesia, dizziness"
        },
        {
          "entity_type": "Effect",
          "entity_name": "loss of coordination",
          "context": "dizziness, loss of coordination"
        },
        {
          "entity_type": "Effect",
          "entity_name": "drowsiness",
          "context": "loss of coordination, drowsiness"
        },
        {
          "entity_type": "Effect",
          "entity_name": "blurred vision",
          "context": "drowsiness, blurred vision"
        },
        {
          "entity_type": "Effect",
          "entity_name": "slurred speech",
          "context": "blurred vision, slurred speech"
        },
        {
          "entity_type": "Effect",
          "entity_name": "ataxia",
          "context": "slurred speech and ataxia"
        },
        {
          "entity_type": "Effect",
          "entity_name": "respiratory arrest",
          "context": "Deaths by respiratory arrest"
        },
        {
          "entity_type": "Effect",
          "entity_name": "sedatives",
          "context": "combination with other sedatives"
        }
      ]
    },
    {
      "chunk_id": "ed84c3787c37f33a7b808294fd9b11e8",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "orphenadrine",
          "context": "orphenadrine (an anticholinergic drug)"
        },
        {
          "entity_type": "Effect",
          "entity_name": "anticholinergic",
          "context": "an anticholinergic drug"
        },
        {
          "entity_type": "Compound",
          "entity_name": "tropicamide",
          "context": "misuse of tropicamide"
        },
        {
          "entity_type": "Effect",
          "entity_name": "anticholinergic",
          "context": "an ophthalmic anticholinergic compound"
        },
        {
          "entity_type": "Effect",
          "entity_name": "mydriasis",
          "context": "short-acting mydriasis"
        },
        {
          "entity_type": "Effect",
          "entity_name": "cycloplegia",
          "context": "and cycloplegia"
        },
        {
          "entity_type": "Compound",
          "entity_name": "tropicamide",
          "context": "tropicamide is typically injected intravenously"
        },
        {
          "entity_type": "Compound",
          "entity_name": "psychoactives",
          "context": "other psychoactives"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Tropicamide",
          "context": "Tropicamide-related psychoactive effects"
        },
        {
          "entity_type": "Effect",
          "entity_name": "psychoactive effects",
          "context": "Tropicamide-related psychoactive effects"
        },
        {
          "entity_type": "Effect",
          "entity_name": "hallucinations",
          "context": "include hallucinations"
        },
        {
          "entity_type": "Effect",
          "entity_name": "open eye dreams",
          "context": "\u201copen eye dreams\u201d"
        },
        {
          "entity_type": "Effect",
          "entity_name": "dysphoria",
          "context": "and dysphoria"
        },
        {
          "entity_type": "Effect",
          "entity_name": "slurred speech",
          "context": "slurred speech"
        },
        {
          "entity_type": "Effect",
          "entity_name": "persistent mydriasis",
          "context": "persistent mydriasis"
        },
        {
          "entity_type": "Effect",
          "entity_name": "hyperthermia",
          "context": "hyperthermia"
        },
        {
          "entity_type": "Effect",
          "entity_name": "tremor",
          "context": "tremor"
        },
        {
          "entity_type": "Effect",
          "entity_name": "convulsions",
          "context": "convulsions"
        },
        {
          "entity_type": "Effect",
          "entity_name": "psychomotor agitation",
          "context": "psychomotor agitation"
        },
        {
          "entity_type": "Effect",
          "entity_name": "tachycardia",
          "context": "tachycardia"
        },
        {
          "entity_type": "Effect",
          "entity_name": "suicidal ideation",
          "context": "suicidal ideation"
        }
      ]
    },
    {
      "chunk_id": "6d44931518b5af36d9f68c30c8493998",
      "entities": [
        {
          "entity_type": "Effect",
          "entity_name": "adverse effects",
          "context": "adverse effects"
        }
      ]
    },
    {
      "chunk_id": "89dffe8e25d257e0f0cc34ab746a6484",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "novel psychoactive substances",
          "context": "Consumers of novel psychoactive substances may self-refer"
        },
        {
          "entity_type": "Disease",
          "entity_name": "acute medical problems",
          "context": "concerned with acute medical or psychiatric problems"
        },
        {
          "entity_type": "Disease",
          "entity_name": "psychiatric problems",
          "context": "concerned with acute medical or psychiatric problems"
        },
        {
          "entity_type": "Effect",
          "entity_name": "behavioural disturbances",
          "context": "cope with the behavioural and psychopathological disturbances"
        },
        {
          "entity_type": "Effect",
          "entity_name": "psychopathological disturbances",
          "context": "cope with the behavioural and psychopathological disturbances"
        }
      ]
    },
    {
      "chunk_id": "eb885e38179f87bba0bc58885b12a612",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "psychoactive molecule",
          "context": "prescribing a psychoactive molecule"
        },
        {
          "entity_type": "Compound",
          "entity_name": "pregabalin",
          "context": "e.g., pregabalin or gabapentin"
        },
        {
          "entity_type": "Compound",
          "entity_name": "gabapentin",
          "context": "pregabalin or gabapentin"
        },
        {
          "entity_type": "Effect",
          "entity_name": "psychoactive",
          "context": "a psychoactive molecule"
        },
        {
          "entity_type": "Disease",
          "entity_name": "misuse",
          "context": "potential for misuse"
        },
        {
          "entity_type": "Disease",
          "entity_name": "neurological disorders",
          "context": "neurological/psychiatric disorders"
        },
        {
          "entity_type": "Disease",
          "entity_name": "psychiatric disorders",
          "context": "neurological/psychiatric disorders"
        },
        {
          "entity_type": "Disease",
          "entity_name": "drug abuse",
          "context": "history of drug abuse"
        },
        {
          "entity_type": "Disease",
          "entity_name": "misuse",
          "context": "signs of misuse"
        }
      ]
    },
    {
      "chunk_id": "acca326643e4b7ff9f8587d1ac88ed8e",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "novel psychoactive substances",
          "context": "Neurochemical profiles of some novel psychoactive substances"
        },
        {
          "entity_type": "Compound",
          "entity_name": "opiate receptors",
          "context": "A classification of opiate receptors"
        },
        {
          "entity_type": "Effect",
          "entity_name": "antinociception",
          "context": "mediate antinociception in animals"
        },
        {
          "entity_type": "Compound",
          "entity_name": "N-(1,2-Diphenylethyl)-piperazine derivatives",
          "context": "N-(1,2-Diphenylethyl)-piperazine derivatives"
        },
        {
          "entity_type": "Compound",
          "entity_name": "4-cyclohexyl-1- [(1R)-1,2-diphenylethyl]-piperazine",
          "context": "Reduction of 4-cyclohexyl-1- [(1R)-1,2-diphenylethyl]-piperazine-induced memory impairment"
        },
        {
          "entity_type": "Effect",
          "entity_name": "memory impairment",
          "context": "piperazine-induced memory impairment of passive avoidance performance"
        },
        {
          "entity_type": "Effect",
          "entity_name": "passive avoidance performance",
          "context": "memory impairment of passive avoidance performance"
        },
        {
          "entity_type": "Compound",
          "entity_name": "\u03c31 receptor agonists",
          "context": "by \u03c31 receptor agonists in mice"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MT-45",
          "context": "MT-45 \u2013 en livsfarlig och potentiellt ototokisk internetdrog"
        },
        {
          "entity_type": "Effect",
          "entity_name": "ototokisk",
          "context": "potentiellt ototokisk internetdrog"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Tilidine hydrochloride",
          "context": "Tilidine hydrochloride"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Analgesic",
          "context": "Analgesic substituted piperidylidene-2-sulfon(cyan)amide derivatives"
        },
        {
          "entity_type": "Compound",
          "entity_name": "substituted piperidylidene-2-sulfon(cyan)amide derivatives",
          "context": "Analgesic substituted piperidylidene-2-sulfon(cyan)amide derivatives"
        },
        {
          "entity_type": "Compound",
          "entity_name": "3\u03b2-(p-substituted phenyl)tropane-2\u03b2-carboxylic acid methyl esters",
          "context": "study of 3\u03b2-(p-substituted phenyl)tropane-2\u03b2-carboxylic acid methyl esters"
        },
        {
          "entity_type": "Effect",
          "entity_name": "ligand binding",
          "context": "Synthesis, ligand binding, QSAR"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cocaine analogs",
          "context": "Highly potent cocaine analogs cause long-lasting increases"
        },
        {
          "entity_type": "Effect",
          "entity_name": "locomotor activity",
          "context": "increases in locomotor activity"
        },
        {
          "entity_type": "Compound",
          "entity_name": "3-(3',4'-disubstituted phenyl)-tropane-2-carboxylic acid methyl esters",
          "context": "binding properties of 3-(3',4'-disubstituted phenyl)-tropane-2-carboxylic acid methyl esters"
        },
        {
          "entity_type": "Compound",
          "entity_name": "monoamine transporter",
          "context": "and monoamine transporter binding properties"
        },
        {
          "entity_type": "Effect",
          "entity_name": "binding properties",
          "context": "monoamine transporter binding properties"
        },
        {
          "entity_type": "Effect",
          "entity_name": "affecting the central nervous system",
          "context": "Compounds affecting the central nervous system"
        },
        {
          "entity_type": "Compound",
          "entity_name": "3\u03b2-phenyltropane-2-carboxylic esters",
          "context": "4. 3\u03b2-phenyltropane-2-carboxylic esters and analogs"
        },
        {
          "entity_type": "Compound",
          "entity_name": "analogs",
          "context": "3\u03b2-phenyltropane-2-carboxylic esters and analogs"
        },
        {
          "entity_type": "Compound",
          "entity_name": "tryptamine",
          "context": "tryptamine and phenylamine use among high-risk youth"
        },
        {
          "entity_type": "Compound",
          "entity_name": "phenylamine",
          "context": "tryptamine and phenylamine use among high-risk youth"
        },
        {
          "entity_type": "Compound",
          "entity_name": "synthetic tryptamines",
          "context": "analysis of the synthetic tryptamines AMT and 5-MeO-DALT"
        },
        {
          "entity_type": "Compound",
          "entity_name": "AMT",
          "context": "synthetic tryptamines AMT and 5-MeO-DALT"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-MeO-DALT",
          "context": "AMT and 5-MeO-DALT"
        },
        {
          "entity_type": "Compound",
          "entity_name": "novel psychoactive drugs",
          "context": "emerging 'novel psychoactive drugs'"
        },
        {
          "entity_type": "Compound",
          "entity_name": "indole derivatives",
          "context": "Simple indole derivatives from Paramuricea chamaeleon"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Ayahuasca analogs",
          "context": "Ayahuasca analogs and plant-based tryptamines"
        },
        {
          "entity_type": "Compound",
          "entity_name": "plant-based tryptamines",
          "context": "Ayahuasca analogs and plant-based tryptamines"
        },
        {
          "entity_type": "Compound",
          "entity_name": "new psychoactive substances",
          "context": "Some new psychoactive substances: precursor chemicals"
        },
        {
          "entity_type": "Compound",
          "entity_name": "precursor chemicals",
          "context": "precursor chemicals and synthesis-driven end-products"
        },
        {
          "entity_type": "Compound",
          "entity_name": "psilocybin",
          "context": "Isolation of psilocybin from Psilocybe argenteipes"
        },
        {
          "entity_type": "Compound",
          "entity_name": "tryptamines",
          "context": "pharmacology of tryptamines and beta-carbolines"
        },
        {
          "entity_type": "Compound",
          "entity_name": "beta-carbolines",
          "context": "tryptamines and beta-carbolines"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-methoxy-N,N-dimethyltryptamine",
          "context": "Biogenesis of 5-methoxy-N,N-dimethyltryptamine in human pineal gland"
        },
        {
          "entity_type": "Compound",
          "entity_name": "N,N-dimethyltryptamine",
          "context": "N,N-dimethyltryptamine: an endogenous hallucinogen"
        },
        {
          "entity_type": "Effect",
          "entity_name": "hallucinogen",
          "context": "an endogenous hallucinogen"
        },
        {
          "entity_type": "Compound",
          "entity_name": "bufotenin",
          "context": "Urinary excretion of free bufotenin by psychiatric patients"
        },
        {
          "entity_type": "Disease",
          "entity_name": "psychiatric patients",
          "context": "by psychiatric patients"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Central stimulant actions",
          "context": "Central stimulant actions of \u03b1-alkyl substituted tryptamine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "\u03b1-alkyl substituted tryptamine",
          "context": "actions of \u03b1-alkyl substituted tryptamine in mice"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Novel psychoactive substances",
          "context": "Novel psychoactive substances: classification, pharmacology and toxicology"
        },
        {
          "entity_type": "Effect",
          "entity_name": "pharmacology",
          "context": "classification, pharmacology and toxicology"
        },
        {
          "entity_type": "Effect",
          "entity_name": "toxicology",
          "context": "pharmacology and toxicology"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Dimethyltryptamine",
          "context": "Dimethyltryptamine and other hallucinogenic tryptamines"
        },
        {
          "entity_type": "Compound",
          "entity_name": "hallucinogenic tryptamines",
          "context": "other hallucinogenic tryptamines exhibit substrate behavior"
        },
        {
          "entity_type": "Effect",
          "entity_name": "substrate behavior",
          "context": "exhibit substrate behavior at the serotonin uptake transporter"
        },
        {
          "entity_type": "Compound",
          "entity_name": "serotonin uptake transporter",
          "context": "at the serotonin uptake transporter and the vesicle monoamine transporter"
        },
        {
          "entity_type": "Compound",
          "entity_name": "vesicle monoamine transporter",
          "context": "and the vesicle monoamine transporter"
        },
        {
          "entity_type": "Effect",
          "entity_name": "behavioural pharmacology",
          "context": "The behavioural pharmacology of hallucinogens"
        },
        {
          "entity_type": "Effect",
          "entity_name": "hallucinogens",
          "context": "pharmacology of hallucinogens"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Hallucinogens",
          "context": "Hallucinogens. Pharmacol Ther 2004"
        },
        {
          "entity_type": "Effect",
          "entity_name": "hallucinogen",
          "context": "The hallucinogen N,N-dimethyltryptamine (DMT)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "N,N-dimethyltryptamine",
          "context": "The hallucinogen N,N-dimethyltryptamine (DMT)"
        },
        {
          "entity_type": "Compound",
          "entity_name": "DMT",
          "context": "N,N-dimethyltryptamine (DMT) is an endogenous sigma-1 receptor regulator"
        },
        {
          "entity_type": "Compound",
          "entity_name": "sigma-1 receptor regulator",
          "context": "an endogenous sigma-1 receptor regulator"
        },
        {
          "entity_type": "Compound",
          "entity_name": "5-methoxy-N,N-diisopropyltryptamine",
          "context": "5-methoxy-N,N-diisopropyltryptamine (Foxy), a selective and high affinity inhibitor"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Foxy",
          "context": "5-methoxy-N,N-diisopropyltryptamine (Foxy)"
        },
        {
          "entity_type": "Effect",
          "entity_name": "inhibitor of serotonin transporter",
          "context": "high affinity inhibitor of serotonin transporter"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Psychoactive",
          "context": "Psychoactive natural products"
        },
        {
          "entity_type": "Compound",
          "entity_name": "natural products",
          "context": "Psychoactive natural products"
        },
        {
          "entity_type": "Compound",
          "entity_name": "bufotenine",
          "context": "Toads and bufotenine: fact and fiction"
        },
        {
          "entity_type": "Effect",
          "entity_name": "psychedelic",
          "context": "an alleged psychedelic"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Psychoactive properties",
          "context": "Psychoactive properties of alpha-methyltryptamine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "alpha-methyltryptamine",
          "context": "properties of alpha-methyltryptamine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "gamma-hydroxybutyric acid",
          "context": "efficacy of gamma-hydroxybutyric acid in treatment of opiate withdrawal"
        },
        {
          "entity_type": "Disease",
          "entity_name": "opiate withdrawal",
          "context": "treatment of opiate withdrawal"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Gamma-hydroxybutyrate",
          "context": "Gamma-hydroxybutyrate (GHB): a scoping review"
        },
        {
          "entity_type": "Compound",
          "entity_name": "GHB",
          "context": "Gamma-hydroxybutyrate (GHB)"
        },
        {
          "entity_type": "Effect",
          "entity_name": "pharmacology",
          "context": "pharmacology, toxicology, motives for use"
        },
        {
          "entity_type": "Effect",
          "entity_name": "toxicology",
          "context": "toxicology, motives for use"
        },
        {
          "entity_type": "Compound",
          "entity_name": "gamma-hydroxybutyric acid",
          "context": "elimination of gamma-hydroxybutyric acid in healthy volunteers"
        },
        {
          "entity_type": "Effect",
          "entity_name": "absorption",
          "context": "Dose-dependent absorption and elimination"
        },
        {
          "entity_type": "Effect",
          "entity_name": "elimination",
          "context": "absorption and elimination of gamma-hydroxybutyric acid"
        },
        {
          "entity_type": "Compound",
          "entity_name": "GHB",
          "context": "risk assessment of GHB in the framework"
        },
        {
          "entity_type": "Compound",
          "entity_name": "new synthetic drugs",
          "context": "joint action on new synthetic drugs"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Physical dependence",
          "context": "Physical dependence on sodium oxybate"
        },
        {
          "entity_type": "Compound",
          "entity_name": "sodium oxybate",
          "context": "dependence on sodium oxybate"
        },
        {
          "entity_type": "Compound",
          "entity_name": "GHB",
          "context": "deaths involving GHB and its analogues"
        },
        {
          "entity_type": "Compound",
          "entity_name": "analogues",
          "context": "GHB and its analogues"
        },
        {
          "entity_type": "Effect",
          "entity_name": "withdrawal symptoms",
          "context": "severe withdrawal symptoms after acute-on-chronic baclofen overdose"
        },
        {
          "entity_type": "Compound",
          "entity_name": "baclofen",
          "context": "acute-on-chronic baclofen overdose"
        },
        {
          "entity_type": "Effect",
          "entity_name": "overdose",
          "context": "baclofen overdose"
        },
        {
          "entity_type": "Compound",
          "entity_name": "gamma-aminobutyric acid",
          "context": "Role of gamma-aminobutyric acid in antipanic drug efficacy"
        },
        {
          "entity_type": "Effect",
          "entity_name": "antipanic drug efficacy",
          "context": "in antipanic drug efficacy"
        },
        {
          "entity_type": "Compound",
          "entity_name": "GABAB agonist",
          "context": "The GABAB agonist baclofen reduces cigarette consumption"
        },
        {
          "entity_type": "Compound",
          "entity_name": "baclofen",
          "context": "GABAB agonist baclofen reduces cigarette consumption"
        },
        {
          "entity_type": "Effect",
          "entity_name": "reduces cigarette consumption",
          "context": "baclofen reduces cigarette consumption"
        },
        {
          "entity_type": "Compound",
          "entity_name": "baclofen",
          "context": "Effects of baclofen on cocaine self-administration"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cocaine",
          "context": "baclofen on cocaine self-administration"
        },
        {
          "entity_type": "Effect",
          "entity_name": "self-administration",
          "context": "cocaine self-administration"
        },
        {
          "entity_type": "Effect",
          "entity_name": "opioid-dependent",
          "context": "opioid- and nonopioid-dependent volunteers"
        },
        {
          "entity_type": "Effect",
          "entity_name": "nonopioid-dependent",
          "context": "nonopioid-dependent volunteers"
        },
        {
          "entity_type": "Compound",
          "entity_name": "baclofen",
          "context": "trial of baclofen for cocaine dependence"
        },
        {
          "entity_type": "Disease",
          "entity_name": "cocaine dependence",
          "context": "baclofen for cocaine dependence"
        }
      ]
    },
    {
      "chunk_id": "eaa7d54932b872331fdfdd199bb75a12",
      "entities": [
        {
          "entity_type": "Compound",
          "entity_name": "Phenazepam",
          "context": "Phenazepam abuse in the UK"
        },
        {
          "entity_type": "Disease",
          "entity_name": "adverse health problems",
          "context": "causing serious adverse health problems"
        },
        {
          "entity_type": "Disease",
          "entity_name": "death",
          "context": "including death"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Olanzapine",
          "context": "Olanzapine as the ideal 'trip terminator'?"
        },
        {
          "entity_type": "Compound",
          "entity_name": "antipsychotics",
          "context": "relating to antipsychotics' use and misuse"
        },
        {
          "entity_type": "Compound",
          "entity_name": "novel psychoactive substance",
          "context": "novel psychoactive substance-related psychotic symptoms"
        },
        {
          "entity_type": "Disease",
          "entity_name": "psychotic symptoms",
          "context": "substance-related psychotic symptoms"
        },
        {
          "entity_type": "Compound",
          "entity_name": "quetiapine",
          "context": "Evaluation of quetiapine abuse and misuse"
        },
        {
          "entity_type": "Compound",
          "entity_name": "atypical antipsychotics",
          "context": "Misuse of atypical antipsychotics"
        },
        {
          "entity_type": "Compound",
          "entity_name": "alcohol",
          "context": "in conjunction with alcohol"
        },
        {
          "entity_type": "Compound",
          "entity_name": "drugs of abuse",
          "context": "and other drugs of abuse"
        },
        {
          "entity_type": "Compound",
          "entity_name": "serotonin",
          "context": "Displacement of serotonin and dopamine transporters"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopamine",
          "context": "and dopamine transporters"
        },
        {
          "entity_type": "Compound",
          "entity_name": "venlafaxine",
          "context": "transporters by venlafaxine extended release capsule"
        },
        {
          "entity_type": "Compound",
          "entity_name": "[125I]2beta-carbomethoxy-3beta-(4-iodophenyl)-tropane",
          "context": "a [125I]2beta-carbomethoxy-3beta-(4-iodophenyl)-tropane single photon emission computed tomography imaging study"
        },
        {
          "entity_type": "Compound",
          "entity_name": "alpha1-adrenoreceptors",
          "context": "The role of alpha1- and alpha2-adrenoreceptors"
        },
        {
          "entity_type": "Compound",
          "entity_name": "alpha2-adrenoreceptors",
          "context": "The role of alpha1- and alpha2-adrenoreceptors"
        },
        {
          "entity_type": "Compound",
          "entity_name": "venlafaxine",
          "context": "on venlafaxine-induced elevation of extracellular serotonin"
        },
        {
          "entity_type": "Compound",
          "entity_name": "serotonin",
          "context": "elevation of extracellular serotonin, noradrenaline and dopamine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "noradrenaline",
          "context": "serotonin, noradrenaline and dopamine levels"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopamine",
          "context": "noradrenaline and dopamine levels"
        },
        {
          "entity_type": "Compound",
          "entity_name": "NPS",
          "context": "The EU early warning system: NPS"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Tropicamide",
          "context": "misuse of Tropicamide collyrium"
        },
        {
          "entity_type": "Disease",
          "entity_name": "Acute psychotic episode",
          "context": "Acute psychotic episode associated with the intake"
        },
        {
          "entity_type": "Effect",
          "entity_name": "testosterone-enhancer",
          "context": "a testosterone-enhancer herbal mixture"
        },
        {
          "entity_type": "Compound",
          "entity_name": "herbal mixture",
          "context": "a testosterone-enhancer herbal mixture"
        },
        {
          "entity_type": "Compound",
          "entity_name": "2,4-dinitrophenol (DNP)",
          "context": "2,4-dinitrophenol (DNP): a weight loss agent"
        },
        {
          "entity_type": "Effect",
          "entity_name": "weight loss",
          "context": "a weight loss agent"
        },
        {
          "entity_type": "Disease",
          "entity_name": "acute toxicity",
          "context": "significant acute toxicity"
        },
        {
          "entity_type": "Disease",
          "entity_name": "death",
          "context": "and risk of death"
        },
        {
          "entity_type": "Compound",
          "entity_name": "DMAA",
          "context": "DMAA as a dietary ingredient"
        },
        {
          "entity_type": "Compound",
          "entity_name": "1,3-dimethylbutylamine (DMBA)",
          "context": "1,3-dimethylbutylamine (DMBA), is identified"
        },
        {
          "entity_type": "Effect",
          "entity_name": "stimulant",
          "context": "A synthetic stimulant never tested in humans"
        },
        {
          "entity_type": "Effect",
          "entity_name": "human enhancement",
          "context": "Heuristics of human enhancement risk"
        },
        {
          "entity_type": "Compound",
          "entity_name": "melanotan",
          "context": "experience of melanotan"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Performance and image enhancing",
          "context": "Performance and image enhancing drugs"
        },
        {
          "entity_type": "Effect",
          "entity_name": "cognitive enhancer",
          "context": "the abuse of cognitive enhancer piracetam"
        },
        {
          "entity_type": "Compound",
          "entity_name": "piracetam",
          "context": "cognitive enhancer piracetam"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Piracetam",
          "context": "Piracetam: a review of pharmacological properties"
        },
        {
          "entity_type": "Effect",
          "entity_name": "pharmacological properties",
          "context": "review of pharmacological properties and clinical uses"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Cerebral blood flow effects",
          "context": "Cerebral blood flow effects of piracetam"
        },
        {
          "entity_type": "Compound",
          "entity_name": "piracetam",
          "context": "effects of piracetam, pentifylline, and nicotinic acid"
        },
        {
          "entity_type": "Compound",
          "entity_name": "pentifylline",
          "context": "piracetam, pentifylline, and nicotinic acid"
        },
        {
          "entity_type": "Compound",
          "entity_name": "nicotinic acid",
          "context": "pentifylline, and nicotinic acid"
        },
        {
          "entity_type": "Compound",
          "entity_name": "acetazolamide",
          "context": "known effect of acetazolamide"
        },
        {
          "entity_type": "Effect",
          "entity_name": "Sexual enhancement",
          "context": "Sexual enhancement products for sale online"
        },
        {
          "entity_type": "Effect",
          "entity_name": "psychoactive effects",
          "context": "awareness of the psychoactive effects of yohimbine"
        },
        {
          "entity_type": "Compound",
          "entity_name": "yohimbine",
          "context": "effects of yohimbine, Maca, Horny Goat Weed and Ginkgo Biloba"
        },
        {
          "entity_type": "Plant",
          "entity_name": "Lepidium meyenii",
          "context": "yohimbine, Maca, Horny Goat Weed and Ginkgo Biloba"
        },
        {
          "entity_type": "Plant",
          "entity_name": "Epimedium",
          "context": "Maca, Horny Goat Weed and Ginkgo Biloba"
        },
        {
          "entity_type": "Plant",
          "entity_name": "Ginkgo biloba",
          "context": "Horny Goat Weed and Ginkgo Biloba"
        },
        {
          "entity_type": "Compound",
          "entity_name": "dopamine",
          "context": "The role of dopamine in schizophrenia"
        },
        {
          "entity_type": "Disease",
          "entity_name": "schizophrenia",
          "context": "dopamine in schizophrenia"
        },
        {
          "entity_type": "Compound",
          "entity_name": "cannabinoid-1 receptors",
          "context": "Activation of cannabinoid-1 receptors"
        },
        {
          "entity_type": "Disease",
          "entity_name": "schizophrenia",
          "context": "relevance to schizophrenia"
        },
        {
          "entity_type": "Compound",
          "entity_name": "serotonin",
          "context": "Alterations in the serotonin system in schizophrenia"
        },
        {
          "entity_type": "Disease",
          "entity_name": "schizophrenia",
          "context": "serotonin system in schizophrenia"
        },
        {
          "entity_type": "Compound",
          "entity_name": "NMDA receptor",
          "context": "chronic NMDA receptor antagonism"
        },
        {
          "entity_type": "Disease",
          "entity_name": "psychosis",
          "context": "models of psychosis"
        },
        {
          "entity_type": "Effect",
          "entity_name": "oxidative stress",
          "context": "Glutamatergic dysbalance and oxidative stress"
        },
        {
          "entity_type": "Compound",
          "entity_name": "\u03ba opioid agonist",
          "context": "effects of the \u03ba opioid agonist Salvinorin A"
        },
        {
          "entity_type": "Compound",
          "entity_name": "Salvinorin A",
          "context": "\u03ba opioid agonist Salvinorin A in humans"
        },
        {
          "entity_type": "Effect",
          "entity_name": "behavioral effects",
          "context": "Dose-related behavioral, subjective, endocrine, and psychophysiological effects"
        },
        {
          "entity_type": "Effect",
          "entity_name": "subjective effects",
          "context": "behavioral, subjective, endocrine, and psychophysiological effects"
        },
        {
          "entity_type": "Effect",
          "entity_name": "endocrine effects",
          "context": "subjective, endocrine, and psychophysiological effects"
        },
        {
          "entity_type": "Effect",
          "entity_name": "psychophysiological effects",
          "context": "endocrine, and psychophysiological effects"
        },
        {
          "entity_type": "Disease",
          "entity_name": "Serotonin syndrome",
          "context": "Serotonin syndrome associated with MDPV use"
        },
        {
          "entity_type": "Compound",
          "entity_name": "MDPV",
          "context": "associated with MDPV use"
        }
      ]
    }
  ],
  "total_entities": 447,
  "extraction_date": "2026-02-01T08:39:36.204190+00:00"
}